Investigational Drug Information for GWP42003-P
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug GWP42003-P?
GWP42003-P is an investigational drug.
There have been 30 clinical trials for GWP42003-P.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2020.
The most common disease conditions in clinical trials are Syndrome, Epilepsy, and Seizures. The leading clinical trial sponsors are GW Research Ltd, University of Utah, and State of Georgia.
There is one US patent protecting this investigational drug and five international patents.
Summary for GWP42003-P
| US Patents | 1,091 |
| International Patents | 5,726 |
| US Patent Applications | 3,386 |
| WIPO Patent Applications | 2,427 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2020-10-01) |
| Vendors | 34 |
Recent Clinical Trials for GWP42003-P
| Title | Sponsor | Phase |
|---|---|---|
| Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy | National Cancer Institute (NCI) | Phase 2 |
| Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy | Mayo Clinic | Phase 2 |
| Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures | Jazz Pharmaceuticals | Phase 3 |
Clinical Trial Summary for GWP42003-P
Top disease conditions for GWP42003-P
Top clinical trial sponsors for GWP42003-P
US Patents for GWP42003-P
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GWP42003-P | See Plans and Pricing | Pharmaceutical formulations | GW Pharma Limited (Cambridge, GB) | See Plans and Pricing |
| GWP42003-P | See Plans and Pricing | Compositions and methods for treating chronic inflammation and inflammatory diseases | Infirst Healthcare Limited (London, GB) | See Plans and Pricing |
| GWP42003-P | See Plans and Pricing | Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols | KANNALIFE SCIENCES, INC. (Huntington, NY) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GWP42003-P
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GWP42003-P | Australia | AU2002231970 | 2021-02-14 | See Plans and Pricing |
| GWP42003-P | Canada | CA2438097 | 2021-02-14 | See Plans and Pricing |
| GWP42003-P | Canada | CA2533400 | 2021-02-14 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
